AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 14 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., (BISP) announced that it has initiated a phase II clinical trial of LibiGel (testosterone gel) for the treatment of female sexual dysfunction (FSD).
The trial, being conducted in the United States and Canada, is a double-blind, placebo-controlled study that will enroll approximately 120 patients to determine the effect of LibiGel on women's sexual desire and activity.
BioSante has completed three phase I/II LibiGel clinical trials to determine blood levels of testosterone delivered by six different doses of LibiGel, which is administered as a topical gel. Data from these studies were presented by Dr. James A. Simon, clinical professor of obstetrics and gynecology at the George Washington University School if Medicine in Washington, DC, during a recent meeting of The North American Menopause Society.
"The data presented at The North American Menopause Society Meeting...indicate that LibiGel delivers the blood levels of testosterone believed to be necessary to improve women's libido," said Stephen M. Simes, BioSante.
LibiGel is a gel formulation of testosterone ...
Source: HighBeam Research, Phase II clinical trial initiated for testosterone gel.(BioSante...